$BLRX

BioLineRx Ltd.

BioLineRx is an Israel-based biopharmaceutical company focused on developing therapies in oncology and rare diseases. It is headquartered in Modi’in, Israel. Its products and programs include motixafortide, marketed in the United States as APHEXDA for stem-cell mobilization in patients with multiple myeloma, and in development for pancreatic cancer and other solid tumors; and GLIX1, an oral small molecule being developed for glioblastoma and other cancers through Tetragon, which BioLineRx owns 40% of with Hemispherian owning the remaining 60%. BioLineRx also has BL-5010, a topical applicator for non-surgical removal of skin lesions, licensed to Perrigo for certain markets. BioLineRx earns money through licensing and collaboration agreements, including upfront payments, potential milestone payments and royalties on motixafortide sales by its partners. It also supplies motixafortide to Ayrmid for commercial and development use on a cost-plus basis.

2
3
0

No SEC Form 4 filings for $BLRX in the last 30 days.

See all $BLRX insider activity →
Med

BioLineRx to Report Third Quarter 2026 Results on November 23, 2026

BioLineRx (NASDAQ: BLRX, TASE: BLRX) will release its Q3 2026 financial results on November 23, 2026, before U.S. market open. A conference call at 8:30 a.m. EST will feature CEO Philip Serlin. The company is a clinical-stage biopharmaceutical firm focused on oncology and rare diseases, with lead asset GLIX1 in Phase 1/2a trials.

BioLineRx sells APHEXDA royalty rights for $5.6 million

BioLineRx (BLRX) sold 14.4% royalty rights to APHEXDA for $5.6M to Soleus Capital. The deal excludes 3.6% royalties. Proceeds will fund R&D, working capital, and partial loan repayment. The transaction is expected to close by November 30, 2026. APHEXDA is an FDA-approved drug for stem cell mobilization in multiple myeloma. BioLineRx is also developing GLIX1 for glioblastoma.

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026

BioLineRx (BLRX) and Hemispherian presented Phase 1/2a clinical study and pre-clinical updates for GLIX1 at the SNO 2026 Annual Meeting. The study, ongoing with no safety concerns, includes a fourth cohort and plans for window-of-opportunity cohorts. GLIX1 showed robust, dose-dependent antitumor activity in multiple glioblastoma models, including brain penetration and dose-dependent increases in tumor 5hmC.

BLRX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BLRX (BioLineRx Ltd.). Coverage has skewed bullish: 2 bullish, 3 neutral, and 0 bearish.

Recent BLRX coverage spans earnings, technology and financial news.

What's driving BLRX

  • This sets a clear earnings-event timeline for BLRX, which can drive positioning and volatility into the Nov. 23 pre-market release.

    prnewswire.com · Nov 18, 2026

  • Royalty-rights sale provides near-term liquidity but reduces ongoing APHEXDA royalty participation; investors may weigh funding benefit versus long-term revenue dilution.

    investing.com · Nov 18, 2026

  • First public data on GLIX1 shows safety and dose‑dependent antitumor activity, likely to lift sentiment.

    prnewswire.com · Nov 16, 2026

  • Positive preclinical results may lift investor sentiment toward BLRX ahead of future clinical readouts.

    prnewswire.com · Oct 23, 2026

  • The announcement signals continued advancement of GLIX1, which may generate modest investor interest.

    investing.com · Oct 8, 2026

AlphAI scores every news story that mentions BLRX with an AI model for sentiment and relevance, and aggregates insider trades from BioLineRx Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BLRX

Score
$BLRXMedEarnings date

BioLineRx to Report Third Quarter 2026 Results on November 23, 2026

BioLineRx (NASDAQ: BLRX, TASE: BLRX) will release its Q3 2026 financial results on November 23, 2026, before U.S. market open. A conference call at 8:30 a.m. EST will feature CEO Philip Serlin. The company is a clinical-stage biopharmaceutical firm focused on oncology and rare diseases, with lead asset GLIX1 in Phase 1/2a trials.

$BLRXMedAI 8/10

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026

BioLineRx (BLRX) and Hemispherian presented Phase 1/2a clinical study and pre-clinical updates for GLIX1 at the SNO 2026 Annual Meeting. The study, ongoing with no safety concerns, includes a fourth cohort and plans for window-of-opportunity cohorts. GLIX1 showed robust, dose-dependent antitumor activity in multiple glioblastoma models, including brain penetration and dose-dependent increases in tumor 5hmC.

$BLRXLowAI 8/10

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026

BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1's synergy with PARP inhibitors in HR-proficient ovarian cancer. GLIX1, a TET2 activator, demonstrated tumor growth inhibition in combination with olaparib, veliparib, and niraparib. BioLineRx plans to add an ovarian cancer arm to its ongoing Phase 1/2a trial for glioblastoma.

$BLRXMedAI 8/10

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx (BLRX) and Hemispherian AS announced preclinical data and trial design for GLIX1, a TET2 activator, will be presented at EANO 2026. GLIX1 showed anti-tumor activity in glioblastoma models, with a Phase 1/2a trial actively enrolling patients. BioLineRx is developing GLIX1 for glioblastoma and other solid tumors.

BLRX: New GLIX1 Data Touts Synergies

BioLineRx (BLRX) reported 2Q 2026 revenues of $294,000 and a net loss of $4.3 million. The company's GLIX1 clinical trial is progressing, with new data showing synergistic effects with a PARP inhibitor. BioLineRx raised $3.75 million in capital to support development. The trial's Phase I/IIa results are expected in 1H 2027.

$BLRXMedEarnings

BioLineRx Ltd. (BLRX): Financial results for Q2 2026

BioLineRx Ltd. (BLRX) furnished an SEC Form 6-K — earnings release. Exhibit 1 For Immediate Release BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data

Related tickers